Floatz logo

PCV 13

Recurrent Marginal Zone Lymphoma

Mayo ClinicvaccinePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

106 Active assets in the Recurrent Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BBB
VINCRISTINE SULFATE
Mayo Clinic
Phase 2BBB

View all 50 →

Same molecule, other indications

PCV 13 is also rated in:

pneumococcal infectionDormant
BB
Indicative ·
64 / 100
View asset →
Small Lymphocytic LymphomaDormant
B
Indicative ·
63 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →